Published April 16, 2012
Sungwon’s agreement means a minimum order of 1.5 million syringes each quarter. Revolutions Medical and Sungwon are currently working to get the syringe registered under the South Korean Food and Drug Administration.
So far, Sungwon has placed an order to be used for initial marketing in the country.
“We have many good relationships with doctors and hospitals in South Korea and feel confident they will be impressed by the RevVac auto-retractable vacuum safety syringe,” said David Hee Lee, managing director of Sungwon Medical.